Mucopolysaccharidosis type II

While children with MPS II appear healthy at birth, early indicators often emerge between ages 2 and 4. Parents should look for a combination of specific signs rather than isolated symptoms. These include a deep, hoarse voice, thick and non-stretchy skin, and a tendency toward frequent respiratory infections. Unlike many other developmental disorders, physical features such as a large head, full lips, and an enlarged tongue are prominent early markers. Additionally, the presence of umbilical or inguinal hernias in a toddler with these facial features is a strong clinical clue that warrants immediate genetic testing. How does the X-linked inheritance pattern affect family planning and carrier testing for female relatives?::Because MPS II is X-linked recessive, it almost exclusively affects males, but females can be carriers. If a male is diagnosed, his mother is likely a carrier, and his sisters have a 50% chance of being carriers. Carrier testing involves measuring I2S enzyme activity in blood or skin cells; however, because female carriers have two X chromosomes, their enzyme levels may be within the normal range or only slightly reduced. Genetic sequencing of the IDS gene is the most accurate method for confirming carrier status. Family planning options include preimplantation genetic diagnosis (PGD) with IVF or prenatal diagnosis via chorionic villus sampling or amniocentesis. What specific respiratory complications require urgent medical attention in patients with MPS II?::Respiratory issues are a leading cause of morbidity and mortality in MPS II due to the accumulation of GAGs in the airway tissues. Patients are at high risk for obstructive sleep apnea, which can lead to chronic hypoxia. Warning signs that require urgent evaluation include severe snoring, gasping for air during sleep, or daytime lethargy. Additionally, frequent lower respiratory tract infections that do not respond to standard antibiotics may indicate significant airway narrowing or mucus plugging. Regular monitoring by a pulmonologist is essential, and some patients may eventually require tracheostomy or continuous positive airway pressure (CPAP) therapy to maintain adequate oxygenation. Is there a cure for MPS II, and how does enzyme replacement therapy impact disease progression?::Currently, there is no cure for MPS II, but hematopoietic stem cell transplantation (HSCT) can be effective if performed early, particularly in the neuropathic form, as it can cross the blood-brain barrier. For patients who are not candidates for HSCT, enzyme replacement therapy (ERT) using idursulfase is the standard of care. ERT helps reduce the accumulation of GAGs in the body, which can improve mobility, reduce organ enlargement, and stabilize respiratory function. However, ERT does not cross the blood-brain barrier, so it does not prevent or reverse neurological decline in the neuropathic form. Treatment is lifelong and requires weekly intravenous infusions.